TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00601276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: Subcutaneous injection, 3.75 mg every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproterone acetate
Description: 2.0 mg/kg/day, tablet, per os
Study: NCT00424931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-17216498
Description: 50mg one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-17216498
Description: 10mg one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg X 2
Study: NCT00916292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF-1 141
Description: Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF-1 141
Description: Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
Study: NCT02388607

Intervention type: OTHER
Intervention: measurements
Description: performance measurements
Study: NCT03086980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Self Transcending Meditation
Description: Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Usual Care will be provided.
Study: NCT04008082

Intervention type: DRUG
Intervention: Lenvatinib
Description: Lenvatinib capsule.
Study: NCT04831931

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program Applied by Telerehabilitation
Description: Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program Applied by Telerehabilitation
Description: Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups.
Study: NCT02397174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediterranean diet, restricted calorie
Description: 50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric diet, restricted calorie
Description: 50 pcos women will be assigned to standardized hypocaloric diet for 6 months
Study: NCT04170049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )
Description: Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
Study: NCT03305783

Intervention type: PROCEDURE
Intervention: cholecystectomy
Description: elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
Study: NCT03899506

Intervention type: DRUG
Intervention: Olanzapine
Description: Patients receiving Olanzapine per the ED protocol

Intervention type: DRUG
Intervention: Midazolam
Description: Patients receiving Midazolam per the ED protocol
Study: NCT02296047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: physiological saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: physiological saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Description: 80 µg inhalation once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Description: 80 µg inhalation once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: 400 µg inhalation once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: 400 µg inhalation once
Study: NCT01220037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhere to a specific standardized diet for 4 days
Description: 24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhere to a specific standardized diet for 4 days
Description: 24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhere to a specific standardized diet for 4 days
Description: 24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhere to a specific standardized diet for 4 days
Description: 24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
Study: NCT04049695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This intervention is based on Control Theory and Social Cognitive Theory and includes: 1) weekly emails with tips and tools to set personalized exercise goals and to increase exercise; 2) Health coaching phone sessions; 3) wrist worn monitor such as a Fitbit to track activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This intervention includes: 1) weekly emails with tips and tools to support health and wellness such as brain health, stress management, nutrition; 2) Health coaching phone sessions
Study: NCT02590978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Description: Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control (Delayed cholecystectomy)
Description: Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed once complete resolution of abdominal tenderness, oral feeding and trending down in pancreatic laboratory is achieved
Study: NCT04078659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Description: Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate infusion
Description: Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients will receive propofol in a dose of 1-2 mg /kg
Study: NCT02835547

Intervention type: OTHER
Intervention: Data collection
Description: Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Study: NCT00520065

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enteral nutritional formula
Description: Meal glucose tolerance test
Study: NCT04203368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
Study: NCT00520065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes specific enteral product
Description: Meal Glucose tolerance test
Study: NCT03034980

Intervention type: OTHER
Intervention: Training intensity (workload) during ergospirometry
Description: The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
Study: NCT02441738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Ablation
Description: The procedure will be performed following standard of care guidelines.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: The procedure will be performed following standard of care guidelines.
Study: NCT00373230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telemedicine
Description: One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
Study: NCT02894645

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: L-Asparaginase
Description: Intramuscular injection

Intervention type: DRUG
Group type: OTHER
Intervention: L-Asparaginase
Description: Intramuscular injection

Intervention type: DRUG
Group type: OTHER
Intervention: L-Asparaginase
Description: Intramuscular injection
Study: NCT04203368

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: verapamil
Description: patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
Study: NCT00946010

Intervention type: BIOLOGICAL
Intervention: blood sampling and abdominal sonography
Description: 10cc blood sampling and abdominal sonography
Study: NCT02447380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094
Description: AZD6094 600MG qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60 mg/m2
Study: NCT04078659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients will receive propofol in a dose of 1-2 mg /kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atracurium
Description: Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atracurium
Description: Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
Study: NCT01385683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran then dabigatran and clarithromycin
Description: D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin and dabigatran then dabigatran
Description: D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
Study: NCT04035733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVA576
Description: BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
Study: NCT00913562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: one tablet rosuvastatin 10 mg per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: one tablet rosuvastatin 10 mg per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet a day for 12 weeks
Study: NCT02536729

Intervention type: DRUG
Intervention: Oral Sodium Phosphate - Normal preparation
Study: NCT04078659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
Study: NCT02515552

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Fibromyalgia Wellness Project
Description: Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
Study: NCT03964090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDD-R
Description: Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDD-R
Description: Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDDI-R
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDDI-R
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
Study: NCT02208388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computed tomography perfusion guided treatment
Study: NCT02536729

Intervention type: DRUG
Intervention: Oral sodium phosphate - Modified Preparation
Study: NCT02208388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional flow reserve guided treatment
Study: NCT00000135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSL-109
Description: 60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
Study: NCT04479488

Intervention type: OTHER
Intervention: Hospital admission
Description: Usual care.

Intervention type: OTHER
Intervention: Non-hospitalization procedures
Description: Usual care.
Study: NCT03989037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-01
Description: IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
Study: NCT03078192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-141, Hyperpolarized 129Xenon gas
Description: XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-141, Hyperpolarized 129Xenon gas
Description: XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon
Study: NCT03909971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: ALK inhibitor-treated ALK-positive NSCL treatment
Study: NCT01883518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine
Description: Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
Study: NCT03904043

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Monday-Friday treatment is strongly recommended

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: -CAPOX can be given as alternative
Study: NCT02536729

Intervention type: DRUG
Intervention: polyethylene glycol + Electrolytes
Study: NCT01348763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 150 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: daily until 10. day then stop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: daily until 10. day then stop
Study: NCT02453971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: German Version of eCHECKUP TO GO
Description: It is an online prevention program targeting alcohol consumption.